Erste Asset Management Investment Blog

6 results for keyword "Pfizer"

Article on tag "Pfizer"

Pharmaceutical Companies Increase Sales, Focus on Innovation and Acquisitions
Pharmaceutical Companies Increase Sales, Focus on Innovation and Acquisitions

Pharmaceutical Companies Increase Sales, Focus on Innovation and Acquisitions

The pharmaceutical industry was able to further increase its sales in the last quarter. The biggest players in the sector are relying on acquisitions and innovations – including the increased use of AI. However, things could get more uncomfortable for pharmaceutical companies in the US market: the future US Secretary of Health and Human Services, Rober F. Kennedy Jr., is considered a critic of the industry and has already spoken out in favor of capping drug prices.

Biotechnology shares ready to stage a comeback?
Biotechnology shares ready to stage a comeback?
(c) pexels.com

Biotechnology shares ready to stage a comeback?

In the first half of 2023, growth shares – and as such, also the biotechnology sector – came under pressure as investors were pivoting towards value shares. But the signs are changing. The possible high in interest rates in Europe and the USA could boost biotech shares again, as ERSTE STOCK BIOTEC fund manager Harald Kober explains in an interview.

Covid Vaccines – From Race to Chase
Covid Vaccines – From Race to Chase
(c) unsplash

Covid Vaccines – From Race to Chase

Covid vaccine distribution has begun in much of the developed world. Politicians, commentators and citizens criticize the slow start to immunizations. But like the Tour de France: What counts is not who wears the yellow jersey during the first stage, but who crosses the finish line first at the end. Three factors are crucial to that: vaccine supply, vaccine distribution and, most importantly, vaccination acceptance.

Covid Vaccine: Pfizer, BioNTech and the beginning of the end?
Covid Vaccine: Pfizer, BioNTech and the beginning of the end?
(c) unsplash

Covid Vaccine: Pfizer, BioNTech and the beginning of the end?

In a press release on November 9, Pfizer gave a first taste of the results of the Phase 3 study of the Covid vaccine, which was jointly developed with German biotech company BioNTech. With an estimated efficacy of 90% and the start of the vaccination campaign possibly as early as January 2021, there is light at the end of the tunnel. But some hurdles still remain.